Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug

French drug maker Sanofi said Wednesday that it will acquire Kadmon Pharmaceuticals for $1.9 billion, bolstering its transplant medicines business with a newly approved treatment for graft-versus-host disease.